The Centers for Medicare and Medicaid Services (CMS) announced October 28 that it will cover renal denervation procedures for patients with uncontrolled hypertension. The decision covers two devices approved by the FDA in 2023, including Recor’s Paradise ultrasound system and Medtronic’s Symplicity Spyral radiofrequency system. The coverage falls under the Coverage with Evidence Development process, […]

The postCMS decision expands hypertension device accessappeared first onRolling Out.